GLP-1 War: A Look At The Epic Pipeline Battle Between Novo Nordisk And Eli Lilly

Core Viewpoint - The article discusses the author's long-term investment in Novo Nordisk (NVO) and reflects on the perceived value of the stock despite current losses, emphasizing a fundamental analysis approach to investing [1]. Group 1: Investment Perspective - The author initially invested in Novo Nordisk when the stock was priced at $80 per share, believing it to be a bargain [1]. - Despite experiencing considerable losses, the author maintains that the initial investment price was reasonable [1]. - The author expresses a preference for fundamental analysis over technical analysis, focusing on actual company performance rather than stock price movements [1]. Group 2: Investor Background - The author is a 27-year-old investor from Italy, with a background in Business Administration and completion of CFA level 1 [1]. - The author has been involved in financial markets for about five years, transitioning from trading to a focus on fundamental analysis [1]. - The investment strategy is characterized by a long-term view and often takes a contrarian approach, primarily investing in stocks and ETFs, with a preference for US companies but also analyzing European and Chinese firms [1].